Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding non-arteritic anterior ischemic optic neuropathy is limited due to its relatively low prevalence and the complexities involved in studying conditions affecting the optic nerve. As NAION affects fewer than 10,000 individuals in the U.S., comprehensive clinical studies have not been extensively conducted. This rarity contributes to the challenges in establishing a clearer clinical profile and understanding potential genetic factors.
To navigate your care for non-arteritic anterior ischemic optic neuropathy, consider consulting with a neuro-ophthalmologist who specializes in optic nerve disorders. They can provide insights into current research and potential treatment options. Although there are no specific patient organizations identified for NAION, resources like the Genetic and Rare Diseases Information Center (GARD) at [rarediseases.info.nih.gov](https://rarediseases.info.nih.gov) can offer valuable support. Additionally, consider participating in clinical trials to contribute to the understanding of this condition and explore potential therapies.
Currently, there are four active clinical trials investigating various aspects of non-arteritic anterior ischemic optic neuropathy. In terms of treatment, several orphan drugs are in development, including a 19 amino acid synthetic peptide NOS-enhancer, Brimonidine, NP-CSIC002, and a synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA. For more information on ongoing trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=non-arteritic%20anterior%20ischemic%20optic%20neuropathy).
Actionable guidance for navigating care for non-arteritic anterior ischemic optic neuropathy
To navigate your care for non-arteritic anterior ischemic optic neuropathy, consider consulting with a neuro-ophthalmologist who specializes in optic nerve disorders. They can provide insights into current research and potential treatment options. Although there are no specific patient organizations identified for NAION, resources like the Genetic and Rare Diseases Information Center (GARD) at [rarediseases.info.nih.gov](https://rarediseases.info.nih.gov) can offer valuable support. Additionally, consider participating in clinical trials to contribute to the understanding of this condition and explore potential therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding non-arteritic anterior ischemic optic neuropathy is limited due to its relatively low prevalence and the complexities involved in studying conditions affecting the optic nerve. As NAION affects fewer than 10,000 individuals in the U.S., comprehensive clinical studies have not been extensively conducted. This rarity contributes to the challenges in establishing a clearer clinical profile and understanding potential genetic factors.
To navigate your care for non-arteritic anterior ischemic optic neuropathy, consider consulting with a neuro-ophthalmologist who specializes in optic nerve disorders. They can provide insights into current research and potential treatment options. Although there are no specific patient organizations identified for NAION, resources like the Genetic and Rare Diseases Information Center (GARD) at [rarediseases.info.nih.gov](https://rarediseases.info.nih.gov) can offer valuable support. Additionally, consider participating in clinical trials to contribute to the understanding of this condition and explore potential therapies.
Currently, there are four active clinical trials investigating various aspects of non-arteritic anterior ischemic optic neuropathy. In terms of treatment, several orphan drugs are in development, including a 19 amino acid synthetic peptide NOS-enhancer, Brimonidine, NP-CSIC002, and a synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA. For more information on ongoing trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=non-arteritic%20anterior%20ischemic%20optic%20neuropathy).
Actionable guidance for navigating care for non-arteritic anterior ischemic optic neuropathy
To navigate your care for non-arteritic anterior ischemic optic neuropathy, consider consulting with a neuro-ophthalmologist who specializes in optic nerve disorders. They can provide insights into current research and potential treatment options. Although there are no specific patient organizations identified for NAION, resources like the Genetic and Rare Diseases Information Center (GARD) at [rarediseases.info.nih.gov](https://rarediseases.info.nih.gov) can offer valuable support. Additionally, consider participating in clinical trials to contribute to the understanding of this condition and explore potential therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding non-arteritic anterior ischemic optic neuropathy is limited due to its relatively low prevalence and the complexities involved in studying conditions affecting the optic nerve. As NAION affects fewer than 10,000 individuals in the U.S., comprehensive clinical studies have not been extensively conducted. This rarity contributes to the challenges in establishing a clearer clinical profile and understanding potential genetic factors.
To navigate your care for non-arteritic anterior ischemic optic neuropathy, consider consulting with a neuro-ophthalmologist who specializes in optic nerve disorders. They can provide insights into current research and potential treatment options. Although there are no specific patient organizations identified for NAION, resources like the Genetic and Rare Diseases Information Center (GARD) at [rarediseases.info.nih.gov](https://rarediseases.info.nih.gov) can offer valuable support. Additionally, consider participating in clinical trials to contribute to the understanding of this condition and explore potential therapies.
Currently, there are four active clinical trials investigating various aspects of non-arteritic anterior ischemic optic neuropathy. In terms of treatment, several orphan drugs are in development, including a 19 amino acid synthetic peptide NOS-enhancer, Brimonidine, NP-CSIC002, and a synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA. For more information on ongoing trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=non-arteritic%20anterior%20ischemic%20optic%20neuropathy).
Actionable guidance for navigating care for non-arteritic anterior ischemic optic neuropathy
To navigate your care for non-arteritic anterior ischemic optic neuropathy, consider consulting with a neuro-ophthalmologist who specializes in optic nerve disorders. They can provide insights into current research and potential treatment options. Although there are no specific patient organizations identified for NAION, resources like the Genetic and Rare Diseases Information Center (GARD) at [rarediseases.info.nih.gov](https://rarediseases.info.nih.gov) can offer valuable support. Additionally, consider participating in clinical trials to contribute to the understanding of this condition and explore potential therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning non-arteritic anterior ischemic optic neuropathy
Updated Jan 28, 2026
FDA has approved the first human trial of Life Biosciences' ER-100, a gene therapy aimed at rejuvenating retinal cells in patients with age-related eye diseases. This Phase 1 study will focus on conditions such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).